Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Paíno, Teresa ^a,c   Sarasquete, María E ^b,c   Paiva, Bruno ^d   Krzeminski, Patryk ^a,c   San Segundo, Laura ^a,c   Corchete, Luis A ^b   Redondo, Alba ^b   Garayoa, Mercedes ^a,c   García Sanz, Ramón ^b,c   Gutiérrez, Norma C ^b,c   Ocio, Enrique M ^a,b,c   San Miguel, Jesús F ^d  

^a Salamanca Spain   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD27 ANTIGEN; DOXORUBICIN; MELPHALAN; SYNDECAN 1; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CELL SUBPOPULATION; CLONOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; SCID MOUSE; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMA CELL; TUMOR CELL LINE;

ANIMALS; BORONIC ACIDS; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; DOXORUBICIN; HETEROGRAFTS; HUMANS; IMMUNOPHENOTYPING; MELPHALAN; MICE, SCID; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; PHENOTYPE; PLASMA CELLS; PRECURSOR CELLS, B-LYMPHOID; PYRAZINES; SYNDECAN-1;

EID: 84899066044     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092378     Document Type: Article

References (50)

1. San-Miguel JF, Mateos MV (2011) Can multiple myeloma become a curable disease? Haematologica 96: 1246-1248.
2. Hamburger A, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846-854. (Pubitemid 8208477)
3. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, et al. (1999) CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12: 1101-1106. (Pubitemid 30033542)
4. Wei A, Juneja S (2003) Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol 56: 406-411. (Pubitemid 36724205)
5. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, et al. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94: 318-323. (Pubitemid 26247990)
6. Jego G, Robillard N, Puthier D, Amiot M, Accard F, et al. (1999) Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 94: 701-712. (Pubitemid 29323884)
7. Jego G, Bataille R, Pellat-Deceunynck C (2001) Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 97: 1817-1822. (Pubitemid 32217251)
8. Calame KL (2001) Plasma cells: finding new light at the end of B cell development. Nat Immunol 2: 1103-1108.
9. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336. (Pubitemid 38326254)
10. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, et al. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190-197. (Pubitemid 351380120)
11. Boucher K, Parquet N, Widen R, Shain K, Baz R, et al. (2012) Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res 18: 6155-6168.
12. Yata K, Yaccoby S (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18: 1891-1897. (Pubitemid 39530021)
13. Chiron D, Surget S, Maiga S, Bataille R, Moreau P, et al. (2012) The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol 156: 679-683.
14. Kim D, Park CY, Medeiros BC, Weissman IL (2012) CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26: 2530-2537.
15. Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, et al. (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 203: 1859-1865. (Pubitemid 44188460)
16. Fuhler GM, Baanstra M, Chesik D, Somasundaram R, Seckinger A, et al. (2010) Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 316: 1816-1828.
17. Christensen JH, Jensen PV, Kristensen IB, Abildgaard N, Lodahl M, et al. (2012) Characterization of potential CD138 negative myeloma "stem cells". Haematologica 97: e18-20.
18. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, et al. (2003) Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 31: 271-282. (Pubitemid 36407603)
19. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, Teixido J (1999) Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 107: 825-834. (Pubitemid 30020157)
20. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand crosslink repair and accounts for melphalan resistance in multiple myeloma cells. Blood 106: 698-705. (Pubitemid 40981268)
21. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, et al. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144. (Pubitemid 36323723)
22. Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de las Heras N, et al. (2011) Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 25: 697-706.
23. Carvajal-Vergara X, Tabera S, Montero JC, Esparis-Ogando A, Lopez-Perez R, et al. (2005) Multifunctional role of Erk5 in multiple myeloma. Blood 105: 4492-4499. (Pubitemid 40720799)
24. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, et al. (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 19: 402-409. (Pubitemid 40403317)
25. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257-2317. (Pubitemid 38072572)
26. Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, et al. (2009) Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113: 3781-3791.
27. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034. (Pubitemid 32937383)
28. Li L, Bhatia R (2011) Stem cell quiescence. Clin Cancer Res 17: 4936-4941.
29. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
30. Bharadwaj S, Liu G, Shi Y, Wu R, Yang B, et al. (2013) Multi-Potential Differentiation of Human Urine-Derived Stem Cells: Potential for Therapeutic Applications in Urology. Stem Cells 31:1840-56
31. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737. (Pubitemid 27298715)
32. Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, et al. (2012) CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 26: 2135-2141.
33. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146: 633-644.
34. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG (2008) PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68: 1820-1825. (Pubitemid 351416567)
35. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
36. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, et al. (2007) Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204: 831-840. (Pubitemid 46631612)
37. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, et al. (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117: 4409-4419.
38. Yaccoby S (2005) The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 11: 7599-7606.
39. Jacak J, Schnidar H, Muresan L, Regl G, Frischauf A, et al. (2013) Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout. J Biotechnol 164: 525-530.
40. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, et al. (2013) Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 121: 318-328.
41. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. (Pubitemid 33041634)
42. Nguyen LV, Vanner R, Dirks P, Eaves CJ (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12: 133-143.
43. Reid S, Yang S, Brown R, Kabani K, Aklilu E, et al. (2010) Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 32: e190-196.
44. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, et al. (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173.
45. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, et al. (2012) ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30: 2100-2113.
46. Dick JE (1996) Human stem cell assays in immune-deficient mice. Curr Opin Hematol 3: 405-409.
47. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, et al. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95: 1056-1065. (Pubitemid 30062731)
48. Van Valckenborgh E, Matsui W, Agarwal P, Lub S, Dehui X, et al. (2012) Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia 26: 1436-1439.
49. Paino T, Ocio EM, Paiva B, San-Segundo L, Garayoa M, et al. (2012) CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 97: 1110-1114.
50. Paino T, Paiva B, San Miguel J (2013) Reply to "Response to"CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype". Haematologica 2012;97(7):1110-1114. Haematologica 98: e10.